BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19563463)

  • 21. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
    Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
    Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
    Qin J; Lei B; Xi L; Liu H; Yao X
    Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II.
    Huang H; Pan X; Tan N; Zeng G; Ji C
    Eur J Med Chem; 2007 Mar; 42(3):365-72. PubMed ID: 17118494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques.
    Tsai KC; Lin TH
    J Chem Inf Comput Sci; 2004; 44(5):1857-71. PubMed ID: 15446846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
    Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
    Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
    Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
    Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors.
    Cormanich RA; Goodarzi M; Freitas MP
    Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents.
    Nayyar A; Malde A; Jain R; Coutinho E
    Bioorg Med Chem; 2006 Feb; 14(3):847-56. PubMed ID: 16214351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into designing the dual-targeted HER2/HSP90 inhibitors.
    Chen CY; Chen CY
    J Mol Graph Model; 2010 Aug; 29(1):21-31. PubMed ID: 20471294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D-QSAR studies of heterocyclic quinones with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment.
    Ryu CK; Lee Y; Park SG; You HJ; Lee RY; Lee SY; Choi S
    Bioorg Med Chem; 2008 Nov; 16(22):9772-9. PubMed ID: 18930405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
    J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
    Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
    Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4D-QSAR analysis of a series of antifungal p450 inhibitors and 3D-pharmacophore comparisons as a function of alignment.
    Liu J; Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(6):2170-9. PubMed ID: 14632469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
    Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
    Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.